Influence of the healthcare pathway on the outcome of patients with infective endocarditis.


Journal

European heart journal. Acute cardiovascular care
ISSN: 2048-8734
Titre abrégé: Eur Heart J Acute Cardiovasc Care
Pays: England
ID NLM: 101591369

Informations de publication

Date de publication:
29 Sep 2022
Historique:
received: 18 10 2021
revised: 21 03 2022
accepted: 11 07 2022
pubmed: 29 7 2022
medline: 4 10 2022
entrez: 28 7 2022
Statut: ppublish

Résumé

To determine the prognosis of patients treated for infective endocarditis (IE) according to their healthcare pathway. To assess how the ESC guidelines are implemented concerning the performance of transoesophageal echocardiography, the use of antibiotic therapy, and the performance of valve surgery; and to compare the epidemiological profile of IE according to the type of centres in which the patients are hospitalized. In a prospective multicentric study including 22 hospitals in the South-East of France, 342 patients were classified into three groups according to their healthcare pathway: 119 patients diagnosed and taken care entirely in a reference centre or hospital with cardiac surgery [Referral Center (RC) group], 111 patients diagnosed and initially taken care in a non-RC (NRC), then referred in a centre including cardiac surgery [transferred to the Referral Center (TRC) group] and 112 patients totally taken care in the NRC (NRC group). One-year mortality was 26% (88 deaths) and was not significantly different between Groups 1 and 2 (20 vs. 21%, P = 0.83). Patients in the NRC group had a higher mortality (37%) compared with patients in the RC and TRC groups (P < 0.001). ESC guidelines were not implemented similarly depending on the healthcare pathway (P = 0.04). Patients in the NRC group were significantly older (P < 0.001) and had more comorbidities (P < 0.001) than patients treated in referral centres. Prognosis of patients with IE is influenced by their healthcare pathway. Patients treated exclusively in NRC have a worse prognosis than patients treated in referral or surgical centres.

Identifiants

pubmed: 35900233
pii: 6651127
doi: 10.1093/ehjacc/zuac088
doi:

Substances chimiques

Anti-Bacterial Agents 0

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

672-681

Subventions

Organisme : PHRCI

Informations de copyright

© The Author(s) 2022. Published by Oxford University Press on behalf of the European Society of Cardiology. All rights reserved. For permissions, please email: journals.permissions@oup.com.

Déclaration de conflit d'intérêts

Conflict of interest: None declared.

Auteurs

Florent Arregle (F)

Cardiology Department, Service de Cardiologie APHM, La Timone Hospital, Boulevard Jean Moulin, 13005 Marseille, France.

Nicolas Iline (N)

APHM, La Timone Hospital, BioSTIC, Marseille, France.

Roch Giorgi (R)

Aix Marseille Univ, APHM, INSERM, IRD, SESSTIM, BioSTIC, Marseille, France.

Mary Philip (M)

Cardiology Department, Service de Cardiologie APHM, La Timone Hospital, Boulevard Jean Moulin, 13005 Marseille, France.

Sandrine Hubert (S)

Cardiology Department, Service de Cardiologie APHM, La Timone Hospital, Boulevard Jean Moulin, 13005 Marseille, France.

Frederique Gouriet (F)

Aix Marseille Univ, IRD, APHM, MEPHI, IHU-Méditerranée Infection, Marseille, France.

Jean Paul Casalta (JP)

Aix Marseille Univ, IRD, APHM, MEPHI, IHU-Méditerranée Infection, Marseille, France.

Frédéric Collart (F)

Department of Cardiac Surgery, La Timone Hospital, Marseille, France.

Alberto Riberi (A)

Department of Cardiac Surgery, La Timone Hospital, Marseille, France.

Hélène Martel (H)

Cardiology Department, Service de Cardiologie APHM, La Timone Hospital, Boulevard Jean Moulin, 13005 Marseille, France.

Sébastien Renard (S)

Cardiology Department, Service de Cardiologie APHM, La Timone Hospital, Boulevard Jean Moulin, 13005 Marseille, France.

Laurence Camoin (L)

Aix Marseille Univ, IRD, APHM, MEPHI, IHU-Méditerranée Infection, Marseille, France.

Anne Claire Casalta (AC)

Cardiology Department, Service de Cardiologie APHM, La Timone Hospital, Boulevard Jean Moulin, 13005 Marseille, France.

Hubert Lepidi (H)

Aix Marseille Univ, IRD, APHM, MEPHI, IHU-Méditerranée Infection, Marseille, France.

Didier Raoult (D)

Aix Marseille Univ, IRD, APHM, MEPHI, IHU-Méditerranée Infection, Marseille, France.

Michel Drancourt (M)

Aix Marseille Univ, IRD, APHM, MEPHI, IHU-Méditerranée Infection, Marseille, France.

Gilbert Habib (G)

Cardiology Department, Service de Cardiologie APHM, La Timone Hospital, Boulevard Jean Moulin, 13005 Marseille, France.
Aix Marseille Univ, IRD, APHM, MEPHI, IHU-Méditerranée Infection, Marseille, France.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH